Together with its Swiss partner Nuesch Development, Livingstone Ventures is involved in development of a Cannabis production facility for the production of CBD oil.
Switzerland has long been among the most progressive countries in Europe in terms of drug laws. The Swiss laws on cannabis possession have traditionally been relatively relaxed. In the early 1990s, Switzerland developed a four-pillar approach to drug policy with the first pillar being prevention, the second treatment, the third harm reduction, and the fourth law enforcement. Thus, prevention and treatment are prioritized over criminalization of users. Switzerland for example allows Cannabis growing up to 1% THC (in other European countries it is 0.2%)
CBD oil is a not psychoactive ingredient of Cannbis and is used for relief from pain and other symptoms without the mind-altering effects of marijuana or certain pharmaceutical drugs. CBD oil is made by extracting CBD from the cannabis plant, then diluting it with a carrier oil like coconut or hemp seed oil. It’s gaining momentum in the health and wellness world, with some scientific studies confirming it may help treat a variety of ailments like chronic pain and anxiety.
The liberal position of the Swiss law and the presence of reputed pharma companies makes Switzerland an excellent country for CBD production. The facility in Switzerland will be developed in cooperation with Swiss pharma companies and seasoned companies in the field of Cannabis production.
Livingstone Ventures is involved in the technical development (implementing Dutch technology) and project management in the FEED phase of the project.
